Disclosed herein are compounds and combinations of compounds for treating a disease or condition, such as cancer.

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

It has been found that the membrane permeability of peptide compounds can be improved by making at least one of amino acids constituting the peptide compound be an amino acid having a side chain capable of forming an intramolecular hydrogen bond.

Compounds and berberine compositions containing such compounds that are useful for reducing nicotine dependency. Methods for administering the berberine compositions are also disclosed. The compounds may have a structure according to Formula (I). In Formula (I) R1, R2, R3, R4, and R5 are independently H or D; R6 and R7 are independently hydrogen, deuterium, halogen, C4 to C8 unsubstituted aryl, C4 to C8 substituted aryl, C2 to C6 unsubstituted heterocycle, C2 to C6 substituted heterocycle, C1 to C6 unsubstituted alkyl, C1 to C6 substituted alkyl, C3-C10 unsubstituted cycloalkyl, C3-C10 substituted cycloalkyl, or R6 and R7 are taken together as ═O or ═S; and R8 and R9 are independently selected from a group consisting of methyl, CHF2, and CF3.

Compounds and berberine compositions containing such compounds that are useful for reducing nicotine dependency. Methods for administering the berberine compositions are also disclosed. The compounds may have a structure according to Formula (I). In Formula (I) R1, R2, R3, R4, and R5 are independently H or D; R6 and R7 are independently hydrogen, deuterium, halogen, C4 to C8 unsubstituted aryl, C4 to C8 substituted aryl, C2 to C6 unsubstituted heterocycle, C2 to C6 substituted heterocycle, C1 to C6 unsubstituted alkyl, C1 to C6 substituted alkyl, C3-C10 unsubstituted cycloalkyl, C3-C10 substituted cycloalkyl, or R6 and R7 are taken together as ═O or ═S; and R8 and R9 are independently selected from a group consisting of methyl, CHF2, and CF3.

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders. The compounds and pharmaceutical compositions of the invention can be utilized to treat various diseases or disorders, such as diabetes, diabetic complications, dyslipidemia, hyperlipidemia, obesity, metabolic syndromes, pre-diabetes, atherosclerosis, heart diseases, neurodegenerative diseases, sarcopenia, muscle atrophy, inflammation, cancer and liver diseases and conditions such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. The compounds of this invention are also useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases.

The invention provides various novel compositions of berberine in combination with pharmacologically active organic acids, and related methods of their use in treating various diseases or disorders. The invention further provides various novel compounds prepared from berberine and pharmacologically active organic acids and prepared from ursodeoxycholic acid and pharmacologically active organic bases, and pharmaceutical compositions thereof, and methods of their preparation and therapeutic use in treating and/or preventing various diseases or disorders. The compounds and pharmaceutical compositions of the invention can be utilized to treat various diseases or disorders, such as diabetes, diabetic complications, dyslipidemia, hyperlipidemia, obesity, metabolic syndromes, pre-diabetes, atherosclerosis, heart diseases, neurodegenerative diseases, sarcopenia, muscle atrophy, inflammation, cancer and liver diseases and conditions such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver. The compounds of this invention are also useful in improving liver functions in chronic viral associated liver diseases and alcohol-related liver diseases.

The present invention relates to novel light-emitting materials. These materials comprise a non-aromatic spiro polycyclic group. This new side chain could reduce the stacking of the light-emitting materials and result in high PLQY.

The present invention relates to novel light-emitting materials. These materials comprise a non-aromatic spiro polycyclic group. This new side chain could reduce the stacking of the light-emitting materials and result in high PLQY.

The present invention provides a mangiferin-6-O-berberine salt and a preparation method thereof, and further provides a use of the mangiferin-6-O-berberine salt for the treatment of diabetics and other diseases as an AMPK activator.